Primobiology is a developer of live microbial drugs for immune diseases, focusing on the development of live microbial drugs for autoimmune diseases. Based on microbiome research, the company focuses on the frontiers of neuroimmunity and intestinal flora, and develops and produces probiotics and their products. Puyuan Bio recently completed its first round of financing. This financing is exclusively invested by Xinghua Dingli Venture Capital, with an investment amount of more than 10 million yuan. The funds obtained from the financing will be used for further functional development and clinical research of its own star strains such as PM002 and PM005, and the market of its own probiotic brand Gibson Development and construction of a fermentation center.
This article is transferred from: https://www.itjuzi.com/investevent/13784583
This site is only for collection, and the copyright belongs to the original author.